Neovacs S.A.'s latest marketcap:
As of 06/15/2025, Neovacs S.A.'s market capitalization has reached $7,158.17. According to our data, Neovacs S.A. is the 49138th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 7,158.17 |
| Revenue (ttm) | 500,272.95 |
| Net Income (ttm) | -37,946,034.7 |
| Shares Out | 2.07 M |
| EPS (ttm) | -217.44 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 06/04/2025 |
Neovacs S.A.'s yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/15/2025 | €7,158.17 | -97.27% | 49138 |
| 12/31/2024 | €151,843 | 45225 |
Company Profile
Neovacs S.A. Overview
Neovacs S.A. is a biotechnology company specializing in the development of therapeutic vaccines for autoimmune, inflammatory, allergy, and cancer diseases. Headquartered in Paris, France, the company leverages its proprietary Kinoid technology to create innovative treatments.
Key Focus Areas
- Autoimmune Diseases: Developing vaccines to modulate immune responses.
- Inflammatory Conditions: Targeting chronic inflammation with therapeutic solutions.
- Allergies: Advancing treatments for allergic disorders.
- Cancer: Exploring vaccine-based approaches for oncology.
Product Pipeline
- IFNa Kinoid: An anti-interferon alpha vaccine currently in:
- Phase IIb clinical trial for lupus erythematosus.
- Phase IIa clinical trial for dermatomyositis.
- IL-4/IL-13 Kinoid: A preclinical-stage vaccine targeting allergies.
Company Background
Founded in 1993, Neovacs S.A. has established itself as a pioneer in therapeutic vaccine development, with a strong focus on addressing unmet medical needs through innovative biotechnological approaches.
Frequently Asked Questions
-
What is Neovacs S.A.'s (EPA-ALNEV) current market cap?As of 06/15/2025, Neovacs S.A. (including the parent company, if applicable) has an estimated market capitalization of $7,158.17 USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Neovacs S.A. (EPA-ALNEV) rank globally by market cap?Neovacs S.A. global market capitalization ranking is approximately 49138 as of 06/15/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.